Study of INBRX-109 in Conventional Chondrosarcoma

Summary

Randomized, blinded, placebo-controlled, Phase 2 study of INBRX-109 in unresectable or metastatic conventional chondrosarcoma patients.

Timeline

Start

2021-09-23

Primary completion

2025-09-30

Completion

2026-12

Outcome

Met primary endpoint

release “Ozekibart met its primary endpoint in chondrosarcoma, demonstrating a statistically significant and clinically meaningful improvement in median progression-free survival compared to placebo.” investorroom.com ↗

Drugs

Indications